A Phase I/II Trial of Tocilizumab (Anti-IL-6 Receptor) plus Intravenous Immunoglobulin (IVIG) for Desensitization (DES) in Difficult to DES Patients

被引：0
|
作者：
Vo, A. [1 ]
Choi, J. [1 ]
Cisneros, K. [1 ]
Kahwaji, J. [1 ]
Toyoda, M. [2 ]
Bongha, S. [2 ]
Ge, S. [2 ]
Peng, A. [1 ]
Villicana, R. [1 ]
Jordan, S. [1 ]
机构：
[1] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA
[2] Cedars Sinai Med Ctr, Transplant Immunol Lab, Los Angeles, CA 90048 USA
来源：
TRANSPLANTATION | 2014年 / 98卷
关键词：
D O I：
10.1097/00007890-201407151-00320
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
1456
引用
收藏
页码：103 / 103
页数：1
相关论文
共 50 条
  • [21] Regulatory T Cell (Treg) and Cytokine Levels Post-Tocilizumab (TCZ, Anti-IL-6R) Desensitization (DES) in HLA-Sensitized Patients (HS Pts).
    Shin, B.
    Ge, S.
    Karasyov, A.
    Watanabe, J.
    Choi, J.
    Lovato, D.
    Vo, A.
    Jordan, S.
    Toyoda, M.
    TRANSPLANTATION, 2014, 98 : 115 - 115
  • [22] Regulatory T Cell (Treg) and Cytokine Levels Post-Tocilizumab (TCZ, Anti-IL-6R) Desensitization (DES) in HLA-Sensitized Patients (HS Pts).
    Shin, B.
    Ge, S.
    Karasyov, A.
    Watanabe, J.
    Choi, J.
    Lovato, D.
    Vo, A.
    Jordan, S.
    Toyoda, M.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2014, 14 : 115 - 115
  • [23] Anti-IL-6 Receptor Nanobody (ALX-0061) Seamless "First-in-Human" Phase I/II POC Study in Patients with Active RA On Stable MTX Treatment
    De Bruyn, Steven
    Gachalyi, Bela
    Rojkovich, Bernadette
    Bruk, Slavomir
    Sramek, Petr
    Korkosz, Mariusz
    Krause, Krzysztof
    Schoen, Pieter
    Sargentini-Maier, Laura
    D'Artois, Joke
    Verschueren, Katrien
    De Swert, Katelijne
    Arold, Gerhard
    Holz, Josefin-Beate
    ARTHRITIS AND RHEUMATISM, 2012, 64 (10): : S561 - S561
  • [24] Efficacy and safety of tocilizumab in monotherapy, an anti-IL-6 receptor monoclonal antibody, in patients with active rheumatoid arthritis: Results from a 24 week double-blind phase III study
    Nishimoto, N.
    Miyasaka, N.
    Yamamoto, K.
    Kawai, S.
    Takeuchi, T.
    Azuma, J.
    Kishimoto, T.
    ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 : 59 - 59
  • [25] Phase II/III trial of hyperimmune anti-COVID-19 intravenous immunoglobulin (C-IVIG) therapy in severe COVID-19 patients: study protocol for a randomized controlled trial
    Ali, Shaukat
    Shalim, Elisha
    Farhan, Farah
    Anjum, Fatima
    Ali, Ayesha
    Uddin, Syed Muneeb
    Shahab, Faisal
    Haider, Mustafa
    Ahmed, Iqra
    Ali, Mir Rashid
    Khan, Sadaf
    Rao, Sadia
    Guriro, Kabeer
    Elahi, Saud
    Ali, Muhammad
    Mushtaq, Tehreem
    Sayeed, Muneeba Ahsan
    Muhaymin, Sheikh Muhammad
    Luxmi, Shoba
    Saifullah
    Qureshi, Saeed
    TRIALS, 2022, 23 (01)
  • [26] Phase II/III trial of hyperimmune anti-COVID-19 intravenous immunoglobulin (C-IVIG) therapy in severe COVID-19 patients: study protocol for a randomized controlled trial
    Shaukat Ali
    Elisha Shalim
    Farah Farhan
    Fatima Anjum
    Ayesha Ali
    Syed Muneeb Uddin
    Faisal Shahab
    Mustafa Haider
    Iqra Ahmed
    Mir Rashid Ali
    Sadaf Khan
    Sadia Rao
    Kabeer Guriro
    Saud Elahi
    Muhammad Ali
    Tehreem Mushtaq
    Muneeba Ahsan Sayeed
    Sheikh Muhammad Muhaymin
    Shoba Luxmi
    Saeed Saifullah
    Trials, 23
  • [27] A phase II multicenter study of CNTO 328, an anti-IL-6 monoclonal antibody, in patients (pts) with relapsed or refractory multiple myeloma (MM)
    Voorhees, P. M.
    Manges, R. F.
    Somlo, G.
    Lentzsch, S.
    Jagannath, S.
    Sonneveld, P.
    Frank, R. C.
    Zweegma, S.
    Wijermans, P. W.
    Thomas, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [28] A phase I, pharmacokinetic (PK), and preliminary efficacy assessment of ALD518, a humanized anti-IL-6 antibody, in patients with advanced cancer
    Clarke, S. J.
    Smith, J. T.
    Gebbie, C.
    Sweeney, C.
    Olszewski, N.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [29] Desensitization (DES) with Intravenous Immunoglobulin and Rituximab (IVIG plus Ritux) Does Not Induce Polyomavirus-JC (JCV) Viremia Pre- and Post-Transpalnt (Tx), Suggesting a Low Risk for Progressive Multifocal Leukoencephalopathy (PML) in Desensitized Patients.
    Toyoda, M.
    Ahn, G.
    Thomas, D.
    Vo, A.
    Suviolahti, E.
    Ge, S.
    Jordan, S. C.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2011, 11 : 191 - 192
  • [30] Impact of Angiotensin II Type I Receptor Antibody Positivity in Highly-HLA Sensitized (HS) Patients Transplanted After Desensitization (DES)
    Vo, A.
    Boutsicaris, C.
    Zhang, X.
    Reinsmoen, N.
    Choi, J.
    Jordan, S.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2016, 16 : 702 - 703
12345